Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 33 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/31/2007 First Published: 5/1/1999


1.		Phase III Randomized Study of Eflornithine in Patients with Low Grade, Superficial Transitional Cell Carcinoma of the Bladder

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				ILEX-DFMO341 N01-CN-25434-01, UCLA-9812049, UF-453-1998, WCCC-CO-98803, NCI-G99-1509, NCT00003814

Last Modified: 6/12/2007 First Published: 6/1/2000


2.		Phase III Randomized Study of Eflornithine (DFMO) for Skin Cancer Prevention in Patients With Previously Treated Stage 0, I, or II Basal or Squamous Cell Skin Carcinoma (Summary Last Modified 09/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Closed				21 and over				NCI				WCCC-CO-9737 NCI-P00-0155, NCT00005884

Last Modified: 2/1/1988


3.		Phase III Randomized Comparison of Radiotherapy vs Combination Chemotherapy with DFMO/MEGAG vs No Postoperative Therapy in Patients with Non-Enhancing Moderately and Mildly Anaplastic Gliomas of the Brain (Summary Last Modified 02/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				5 to 45				NCI				NCOG-6G871 BTRC-8625, MDA-DM-88056, NCI-T86-0226D, T86-0226

Last Modified: 2/1/1992


4.		Phase III Trial of Accelerated Hyperfractionation with or without DFMO vs Single Fraction Radiotherapy with or without DFMO in Patients with Newly Diagnosed Glioblastoma Multiforme (Summary Last Modified 02/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				over 18				NCI				BTRC-6G901 NCI-T91-0047O, T91-0047

Last Modified: 6/27/2006


5.		Phase III Randomized Trial of Procarbazine, Lomustine, and Vincristine (PCV) With or Without Eflornithine in Patients with Malignant Gliomas Previously Treated With Radiotherapy (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				16 and over				NCI				MDA-DM-92035 NCI-T92-0114C, T92-0114

Last Modified: 12/18/2006 First Published: 6/25/2005


6.		Phase III Randomized Chemoprevention Study of Eflornithine and Sulindac in Patients With a History of Adenomatous Polyps of the Colon

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Closed				40 to 80				NCI				UCIRVINE-UCI-2002-2261 NCT00118365

Last Modified: 2/1/1998 First Published: 10/1/1997


7.		Phase I/II Chemoprevention Study of Eflornithine (DFMO) in Patients At Risk for Colorectal Carcinoma (Summary Last Modified 02/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Prevention				Closed				Over 18				NCI				WCCC-CO-9221 NCI-P97-0096


8.		Phase I/II Chemotherapy with DFMO/MGBG in Patients with Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				MSKCC-8525A NCI-T85-0043D, T85-0043

Last Modified: 1/1/1999


9.		Phase II Chemoprevention Study of Difluoromethylornithine (DFMO) in Patients With Superficial Bladder Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention, Screening				Closed				18 and over				NCI				WCCC-CO-9285 NCI-G97-1213

Last Modified: 5/1/1999


10.		Phase II Study of DiFluoroMethylOrnithine (DFMO) in Breast Dysplasia with Biomarker Abnormalities (Summary Last Modified 05/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Closed				30-55 with exceptions				NCI				KUMC-HSC-6916-96 NCI-P97-0080

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute